Ratings by Janney (Yun Zhong)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/1/2020 | Y-mAbs Therapeutics | YMAB | New Coverage | Buy (N/A) |
33.58 (8.61) |
-74.36% | Details | |
| 12/30/2019 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 9/11/2019 | Neurotrope | NTRP | Downgrade | Neutral (Buy) |
0.92 (2.09) |
127.17% | Details | |
| 7/21/2019 | Marker Therapeutics | MRKR | Maintain | Buy (N/A) |
|
Details | ||
| 6/11/2019 | uniQure BV | QURE | Maintain | Buy (N/A) |
|
Details | ||
| 5/14/2019 | INSYS Therapeutics | INSY | Downgrade | Neutral (Buy) |
3.60 (0.29) |
-91.94% | Details | |
| 3/5/2019 | Nightstar Therapeutics | NITE | Downgrade | Neutral (Buy) |
15.16 (37.01) |
144.13% | Details | |
| 3/1/2019 | Marker Therapeutics | MRKR | New Coverage | Buy (N/A) |
6.35 (1.47) |
-76.85% | Details | |
| 12/19/2018 | INSYS Therapeutics | INSY | New Coverage | Buy (N/A) |
4.80 (3.60) |
-25% | Details | |
| 11/12/2018 | Denali Therapeutics Inc. | DNLI | New Coverage | Buy (N/A) |
17.35 (25.83) |
48.88% | Details | |
| 11/5/2018 | bluebird bio | BLUE | Upgrade | Buy (Neutral) |
130.15 (4.97) |
-96.18% | Details | |
| 8/22/2018 | Nightstar Therapeutics | NITE | New Coverage | Buy (N/A) |
19.73 (15.16) |
-23.16% | Details |
